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Abstract: Salivary diagnostics is a rapidly advancing field that offers clinicians and patients the
potential of rapid, noninvasive diagnostics with excellent accuracy. In order for the complete
realization of the potential of saliva, however, extensive profiling of constituents must be conducted
and diagnostic biomarkers must be thoroughly validated. This article briefly overviews the process
of conducting a study of salivary biomarkers in a patient cohort and highlights the studies that
have been conducted on different classes of molecules in the saliva. Emerging frontiers in salivary
diagnostics research that may significantly advance the field will also be highlighted.
Keywords: salivary diagnostics; noninvasive; biomarkers
1. Introduction
Molecular diagnostics is the collection of techniques used to analyze and monitor biological
markers associated with diseases. In the field of molecular diagnostics, this involves intensive studies
of patient cohorts in order to discover and validate the molecular constituents that make a diseased
patient differ from a healthy individual. Salivary diagnostics is a rapidly advancing field in molecular
diagnostics. Studies have shown that saliva contains various molecular compounds, such as nucleic
acids and proteins that have been linked to abnormalities and complications from illnesses [1,2].
Currently, scientists have shown that these salivary constituents are effective indicators of many
disorders. Multiple proteomic, transcriptomic, and microbiological markers have been identified
for various pathologies: some prominent studies have been oral cancer, breast cancer, lung cancer,
pancreatic cancer, and Sjögren’s syndrome [3–6].
In addition to the fact that research is readily demonstrating saliva as a viable biofluid for
performing detection, it is also readily evident that saliva has many practical advantages compared to
traditional diagnostic mediums of performing tests for disease diagnostics. In comparing the workflow
for blood-based collection to saliva-based collection, Yoshizawa et al. [3] notes that there are some
clinical advantages to using saliva:
1. Saliva collection is undemanding: procurement of saliva does not require highly trained
personnel, and can be performed easily and readily, in contrast with blood sampling. To obtain
sample saliva, expensive tools are not necessary.
2. Saliva collection is noninvasive: Individual patients are usually more comfortable with saliva
sampling, and are more likely to participate.
3. Saliva samples are easier to handle and store: secretions in saliva that are not present in serum or
plasma help decrease the risk of HIV transmission, and saliva does not clot.
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Ultimately, the selection of saliva when compared to other diagnostic biofluids will be based on
both the specific molecular constituents that are targeted and the practicalities of sample collection and
processing. For example, urine is a molecularly rich biofluid that is useful in various diagnostic [7,8]
scenarios and can be collected relatively easily. However, urine may be inferior for microRNA-based
disease detection, as saliva has been found to have a lower microRNA content than urine or
cerebrospinal fluid [9]. Healthcare professionals and scientists must work in cooperation to holistically
determine the most compelling biofluid for performing diagnostic tests.
This review presents the current state of saliva diagnostics, broadly overviewing investigations
into salivary constituents and considerations that must be made in the process. We will finally discuss
the validation of obtained biomarkers by consulting the six existing “omics” libraries: proteome,
transcriptome, immunome, microbiome, metabolome, and epigenome. Key technologies and findings
used in investigations will be emphasized, along with highlights regarding the future frontiers of
salivary molecular diagnostics.
2. Properties of Saliva as a Diagnostic Fluid
Oral fluid, or saliva, is a clear, slightly acidic (pH = 6.0–7.0), and heterogeneous biological
fluid consisting of secretions primarily from the parotid, submandibular, and sublingual glands [10].
The average daily flow of whole saliva is between 1 and 1.5 L. Physiologically, the function of saliva
includes oral digestion, taste, lubrication, antibacterial protection, and buffering [10–14]. Saliva
contains enzymes, hormones, antibodies, antimicrobial constituents, and cytokines—all of which are
constituents gathered within the salivary glands and subsequently released into the oral cavity through
small ducts by a cluster of cells called acini [11].
Many constituents are found to enter saliva from the blood as part of the endocrine system
by transcellular (e.g., passive and active transport) or paracellular (e.g., extracellular ultrafiltration)
means [15,16]. Because each of the salivary glands is encapsulated by capillaries, each gland is allowed
free exchange of blood-based molecules into the adjacent saliva-producing acinus cells. Previous
research has suggested that circulating biomolecules that originate from a diseased process from the
bloodstream may eventually be transported into the salivary glands, which will then consequently
modify and change the composition of saliva [3–5]. Hence, it is of recent interest to locate saliva-based
targets to evaluate an individual’s current state of health, as saliva is functionally equivalent to blood
plasma or serum in diagnostic medicine.
3. Biomarker Development and Clinical Reality
Biomarker Background
The key to salivary diagnostics is the proper identification, validation, and detection of biomarkers
related to disease. A biomarker refers to a quantifiable biological parameter that is measured and
evaluated as an indicator of normal biological, pathogenic, or pharmacologic responses to a therapeutic
intervention, according to the National Institutes of Health (NIH) [17]. This interaction may be
functional or physiological, biochemical at a cellular level, or of molecular and conformational
nature [18]. Biomarkers encompass a variety of classes: DNA, RNA, metabolites, proteins, and
microbes. The usage of saliva as the diagnostic medium for molecular diagnostics of disease involves
a thorough assessment of individual biomarkers and their relationship to one or more particular
diseases, and also the study of an aggregate group of biomarkers to determine whether they can be
used simultaneously for effective disease detection. This collection of biomarkers used for the diagnosis
of disease is called a molecular signature. To properly identify the key markers that are correlated with a
disease, researchers must perform a rigorous process of recruiting the appropriate patients, collecting
samples in a uniform fashion, and performing discovery assays on specimens. There are specific
considerations that must be made in each step of identifying and validating a salivary biomarker.
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Study Design: The identification of a salivary biomarker begins with identifying a clinical scenario
where saliva may be useful and then ensuring that the design of the study is rigorous enough for
clinical practice. The prospective randomized open blinded end-point (PROBE) study design [19,20] is
a developed framework that provides useful guidelines for conducting a study in a fashion that reduces
bias and improves the likelihood of a positive outcome for biomarker development. The PROBE study
design, for example, recommends that collection of samples be as close to the actual clinical scenario
as possible for differentiation between a healthy and unhealthy subject using a biomarker. Further, as
with any clinical study, proper weighing of the statistical power necessary for reaching validation is
dependent on a host of factors, such as the feasibility of acquiring samples and the desired confidence
levels that are hoped to be achieved by the study. It is critical that scientists and clinicians engage in
active discussion to ensure that the clinical context for detection is well understood.
1. Sample Collection and Processing: Following the selection of the clinical scenario, the sample
collection and processing phase is the next important phase of the study that must be
well-regulated. In traditional collection of blood samples for testing of biomarkers, trained
personnel must perform venipuncture, collect blood samples in vacuum tubes, and then process
the samples to remove red blood cells. Saliva collection, inasmuch as it does not require
venipuncture, can be done more conveniently and efficiently by laypeople and physicians,
increasing the probability of a study’s success. However, in a similar fashion to blood-based
testing, saliva-based testing still requires some specific parameters to be set by the study designer
and to be uniformly applied during the collection phase of experimental work. Table 1 includes a
preliminary assessment of some clinical considerations that must be made when collection saliva.
2. Laboratory Analysis of Biomarkers: Regardless of the specific molecular constituents that are being
targeted (i.e., the test could be in relation to the proteome, transcriptome, genome, microbiome,
metabolome, epigenome, etc.), the portion of study following study design and sample collection
must take into account a proper laboratory workflow for processing the samples and ensuring
that their sample quality is adequate for performing discovery or validation work. In this
phase, it is necessary for the study to have well-designed quality control steps, thorough sample
inventorying and storing (for future reference), and thorough documentation of the workflow for
future reference and reproducibility. These steps must be taken in addition to the parameters that
must be optimized for the specific technical procedures themselves.
Table 1. Considerations regarding the collection and sample processing steps of saliva.
Parameter Description
Subject Status
Prior to collection of samples, study researchers should prescribe either fasted
or unfasted states to patient cohorts. It has been observed that saliva in a
fasted state may lead to differences in composition of saliva [21].
Sample Collection Time
When instructing patients on sample collection, it is necessary to specify a
window of time that the patient may be allowed to contribute their saliva to a
sample collection instance. These windows are important precautions against
sample degradation if the time is long, and also allow adequate time for
saliva to be collected with biomarker content.
Sample Collection Volume
Requirement
Typically, running biomarker identifications or bioassays on a salivary sample
will require a specific volume that must be collected for running tests. If the
subject has a pathology that severely limits the flow of saliva to the oral cavity,
it may be necessary for the study to have modifications made to account for
the reduced volume that may be achievable.
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Table 1. Cont.
Parameter Description
Sample Collection Method
A multitude of different saliva collection methods can be used for testing.
Typical collection protocol used at facilities such as UCLA involves the usage
of traditional falcon tubes on ice, but saliva collectors have also been explored
for collection [22]. This method can be designated as “unstimulated” since it
uses saliva that has naturally pooled in the mouth. This is differs from the
class of “stimulated” collection, where samples of saliva are attained through
methods such as absorbent pads or chewing on parafilm [23]. The methods
used must be appropriately identified, as results of analysis may differ
depending on the saliva collection method.
Sample Processing and Storage
Collections of saliva must be properly optimized based on desired targets to
be tested for. The inclusion of constituents in the saliva such as epithelial cells
may contribute background that may hinder assessments of whether
molecular targets are truly in the saliva. For this reason, centrifugation may
be considered for removing cells and creating cell-free saliva. Stabilizing
agents may be necessary for preservation of samples, depending on the target.
4. Varieties of Biomarkers for Diagnostics in Saliva
There are many technologies employed to measure these biomarker targets, even within specific
categories. The method for evaluation of proteomic, metabolomics, and microbiomic constituents
include liquid chromatography, gel and capillary electrophoresis, nuclear magnetic resonance,
immunoassays, magnetic bead immunoprecipitation, and mass spectrometry [24–26]. Each individual
technique that is used has its respective merits and disadvantages for the various phases of a biomarker
study. For example, in identifying genomic disease targets, techniques such as microarray or deep
sequencing may be appropriate, but following the discovery of a biomarker scientists may want to
change to a different technique such as quantitative polymerase chain reaction (qPCR) or droplet
digital PCR (ddPCR), inasmuch as these may more suitable for the scales necessary for a definitive
validation of a biomarker.
Biomedical research is a dynamic environment, with constant new developments and paradigms.
There are always new frontiers opened up for investigation, partially because new technologies
allow us to perform more detailed and sensitive detection of biomolecule targets, partially because
our understanding of the biology of disease increases daily. Consequently, the specific molecular
constituents that can be investigated for saliva diagnostics is an ever-increasing list. Nevertheless,
at present it is possible to divide investigations of salivary molecular diagnostics into a few
broad categories: proteomic, microbiome, immunologic, genomic (transcriptomic and epigenome),
and metabolomics.
4.1. Proteomics
The proteome refers to all the individual proteins that may make up a biological system.
A systemic study of all salivary secretory proteome (components with all the numerous
post-translational modifications and protein–enzyme complexes) was implemented when the National
Institute of Dental and Craniofacial Research (NIDCR) began to work towards a comprehensive
catalogue of the human salivary proteome. In 2007, a collection of 1166 diverse proteins was
recorded within the human salivary proteome [24,26]. This study was conducted using protein
mass spectroscopy and 2D gel-electrophoresis, in addition to comparing these results with previously
gathered protein databases.
While investigating the differences in salivary protein composition with that in plasma,
Schulz et al. in 2013 reviewed a data set of proteins in plasma compiled by previous studies in
the international Human Plasma Proteome Project, and found that approximately 30% of whole saliva
proteins are found in plasma [27]. This overlap shows reasonable connections that can be drawn
between the salivary proteome and different parts of the body [2]. As other studies have further shown,
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the salivary proteome can be used to draw connections between saliva and cystic fibrosis, diabetes,
periodontitis, dental caries, and acquired immune deficiency syndrome (AIDS) [28–32]. Salivary
proteomic analysis may even be useful for health safety applications such as radiation exposure [33–35].
A particularly compelling application of salivary proteomic biomarkers is the application to oral
squamous cell carcinoma (OSCC). OSCC constitutes 90% of all cases of head and neck cancer. Despite
the oral cavity being very accessible, most cases of OSCCs are not detected until the cancer has
developed into advanced stages. There is much research effort dedicated to investigating salivary
biomarkers as reliable early stage diagnostic analytes. As Cheng et al. and Yakob et al. have reported in
their reviews of salivary biomarkers for oral cancer detection in 2014, more than 100 different salivary
constituents have been suggested as potential OSCC markers [36,37]. Identified discriminatory cancer
markers include matrix metalloproteinases (i.e., MMP1, MMP3, MMP9), cytokines (i.e., interleukin-6,
interleukin-8, vascular endothelial growth factor A (VEGF-A), tumor necrosis factor α (TNF-α),
transferrins, and fibroblast growth factors. Recently, Gleber-Netto et al. elucidated on and further
confirmed results of previous studies, using ELISA and a two-marker univariate fractional polynomial
(FP) model [38], and demonstrated that combining multiple salivary analytes allowed for the greatest
degree of distinguishing oral squamous cell carcinoma from controls and also from other potentially
malignant oral disorders. The combinatory models of IL-8 protein with IL1-β protein and of IL-8
protein with H3 histone family member 3A (H3F3A) mRNA both yielded an area under the curve
(AUC) value of approximately 0.87. Additionally, mass spectrometry-based techniques have revealed
that a combination of the protein markers—myeloid-related protein 14 (MRP14), profilin, cluster of
differentiation 59 (CD59), catalase, and Mac-2-binding protein (M2BP)—yields a sensitivity of 90% and
specificity of 83% for OSCC detection [39].
Saliva analysis has also been shown to diagnose more distal systemic malignancies such as breast
cancer, lung cancer, ovarian cancer, and pancreatic cancer [40–45]. The main goal of these studies has
been the discovery, verification, and validation of a panel of protein biomarkers so that they can be
used in early detection of indicated diseases. Bigler et al. suggests that the protein expression of a
receptor tyrosine kinase oncogene c-erbB-2 in saliva can be helpful to measure patient response to
chemotherapy for treatment of breast cancer; Zhang et al. reports the de novo discovery and validation
of eight mRNA biomarkers and one protein biomarker (carbonic anhydrase 6 (CA6) protein) for the
noninvasive detection of breast cancer, drawing from two-dimensional difference gel electrophoresis,
RT-qPCR, and protein immunoblot techniques [40,41]. Likewise, Xiao et al. utilized 2-D difference gel
electrophoresis and mass spectroscopy to identify 16 candidate protein biomarkers to discriminate lung
cancer patients from healthy control patients, and 3 of these (haptoglobin hp2 (HP), α2-glycoprotein
(AZGP1), and human calprotectin) showed reliable discriminatory power, with 88.5% sensitivity and
92.3% specificity with an AUC of 0.90 [46].
At present, one of the major diseases being moved forward to definitive validation is primary
Sjögren’s syndrome (SS). Patients with SS have a systemic autoimmune disease and suffer from
irreversible damage of salivary and lacrimal glands. This damage is the result of progressive
inflammation of the exocrine glands, stemming from an overexpression of human leukocyte
antigen–antigen D related (HLA-DR) and lymphocytic infiltration of glandular tissue. This disease
may occur as primary SS (pSS) or as a secondary disease associated with other autoimmune diseases
such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). Researchers who study the
proteomics of Sjögren’s syndrome look closely at the production of cytokines (i.e., interferons and
interleukins) and the downstream signaling pathway molecules as overexpressed or underexpressed
constituents of saliva, in afflicted individuals versus a control population. Using mass spectrometry,
Hu et al. and other studies identified and further verified candidate proteins cathepsin D (CPD),
α-enolase, and β2-microglobulin (B2M) as biomarkers that can discriminate primary SS from both
systemic lupus erythematosus and healthy patients [43–45]. Additionally, statistical analysis showed
that combining all three biomarkers yielded even higher sensitivity and specificity values compared to
using them individually. At present, researchers at the UCLA School of Dentistry are engaged in a
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definitive validation of a panel of these SS biomarkers, evaluating a panel of markers with subjects at
multiple clinical sites. A salivary biomarker test for Sjögren’s syndrome would be a valuable accessory
to clinicians, as it would provide a noninvasive and convenient method of assessing SS without the
need for biopsy.
4.2. Immunomics
Using immunological markers of systemic infections to diagnose and prognosticate patients is
another sector of investigation in salivary diagnostics. Immunomic approaches to the characterization
and clinical identification of salivary biomarkers have been utilized by researchers for instances
of infections from HIV virus, hepatitis A, B, and C. The aforementioned mechanisms of molecular
transport of substances from blood serum into salivary gland ducts stem from the fact that salivary
glands are highly vascularized and can uptake blood-based constituents. As such, the number of
immunological markers (which are absorbed and subsequently secreted by the salivary glands into the
oral cavity) are surprisingly comparable in concentration to immunological markers in the vascular
system [44].
One development and application of salivary diagnostics in immunological salivary diagnostics is
the marketing of FDA-approved testing kits for AIDS. Studies have also been conducted to determine
whether or not the hepatitis A virus can be monitored through IgM, IgA, and IgG tests, and hepatitis B
virus and hepatitis C virus through detection of altered IgG levels. Hepatitis A, B, and C are
usually diagnosed through blood draws, but the noninvasive nature of saliva draws has its appeals.
Although the immunoassays performed for hepatitis C virus antibodies possess an accuracy of 97.5%,
the FDA has not approved of this technique yet. Finally, IgG antibodies directed against specific
Plasmodium falciparum antigens, dengue virus antigens, and Ebola virus antigens can be also detected
in saliva. Utilizing saliva to detect these disorders is a process that is well underway, but continued
research is necessary to expand the now commercially available HIV tests to include a wider variety
of microbes.
In the research conducted at UCLA regarding the definitive validation of SS markers, research
on SS in the proteome has been paired with immunologic analysis, as the two profiles present strong
candidates for building a molecular profile for SS. Studies from many groups have demonstrated
the presence of many autoantibodies in whole saliva collected from pSS patients, including
IgA and IgM rheumatoid factor, anti-Ro/SSA, anti-La/SSB, anti-spectrin, anti-Ro52, anti-Ro60,
anti-transglutaminase, and muscarinic acetylcholine receptor (mAChR) IgA [45,47–51]. These studies
report that these pSS-related autoantibodies are able to discriminate patients with SS from both patients
with systemic lupus erythematosus and healthy individuals. The use of SS immunological biomarkers
to help diagnose, classify, and predict the prognosis of patients with pSS has never looked better, and
may become an extremely helpful complement to investigations using other SS protein biomarkers.
4.3. The Salivary Microbiome
Following the Human Microbiome Project, established by the NIH, many studies have
investigated the amount of microbiological flora in the oral cavity, some estimating approximately
500–1000 bacterial species and others reporting up to 10,000 species in the mouth [3,52–55].
Common techniques employed by researchers are bacterial microarrays, DNA hybridization, PCR,
next-generation sequencing, and quantitative 16S rRNA gene sequencing. Most recently and most
promising is the employment of an oligonucleotide microarray based on 16S rRNA, aptly named
human microbe identification microarrays (HOMIM) [3,52–55]. HOMIM has been used in studies using
cohorts of individuals with disease versus control cohorts, in order to detect species of microbiota.
The aim is to identify pathogenic profiles, monitor changes, and map the discovered alterations
to diseases, of which many have been found to be correlated to microbiota. Consequently, such
epidemiologic investigations can allow researchers to assess risk of disease based on HOMIM-based
targeted characterization by comparing to already databased phyla or genera. Infectious diseases, local
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diseases, and systemic diseases that have been identified are HIV-1, HIV-2, hepatitis A, hepatitis B,
hepatitis C, malaria, dengue fever, tuberculosis, Ebola virus disease, herpes simplex, disease caused by
and correlated to Epstein-Barr virus, herpesviruses infection, cytomegalovirus-caused illnesses, oral
cancer, Crohn’s disease, pancreatic cancer and chronic pancreatitis, periodontal disease, dental caries,
and obesity [53–72].
Utilizing HOMIM, Farrell et al. evaluated the oral microbiota of individuals diagnosed with either
pancreatic cancer or chronic pancreatitis and determined these microbiota as potential markers [72].
Following this discovery phase, verification was performed using qPCR on a broader range of
subjects. This work showed the validation of two oral bacterial candidates, Neisseria elongate and
Streptococcus mitis, as microbial biomarkers with high accuracy (96.4% sensitivity and 82.1% specificity)
in distinguishing pancreatic cancer patients from healthy ones.
As studies indicate, understanding how alterations in the microbiome relate to local and systemic
diseases could allow for early detection and for proper prognosis and treatment for particular
pathologies. Research conducted on the salivary microbiome is suggestive about the potential of
correlating bacterial profiles in the saliva with different oral and systemic diseases.
4.4. Genomics—Transcriptomics and Epigenomics
Salivary transcriptomics is based on the analysis of the oral transcriptome—the set of all mRNA
molecules that can be found in the salivary milieu. Broadly speaking, in order to analyze the
transcriptome of a patient, saliva is collected and then DNA/RNA extraction is performed. Following
the extraction, the DNA/RNA is amplified for analysis. After quantification of the nucleic acid content
present in the saliva, comparisons can be made with known transcriptomic information. Technologies
used to detect and analyze genomic and transcriptomic include gene chip arrays, DNA hybridization,
qPCR, and gel electrophoresis [73].
An example study where the transcriptomic profile was examined in a patient population was
conducted by Li et al. on a cohort of OSCC patients, extracting RNA from unstimulated cell-free
saliva and then performing microarray analysis in order to identify candidate genes with altered
expression levels [74]. Following the microarray study, seven mRNA markers that had higher
expression levels were selected and tested for in remaining saliva samples using qPCR. This study
found that a combination of these mRNA markers was able to yield a clinical sensitivity of 91% and
a clinical specificity of 91%. For salivary biomarkers based on transcriptomics, breast cancer and
Sjögren’s syndrome have also been identified and appropriately validated [41,75].
Salivary transcriptomic profiling has also been applied on a mouse model in order to better
understand the salivary transcriptome. In a study by Gao et al., researchers compared the
transcriptomes of the tumor, serum, salivary glands, and saliva on tumor-bearing mouse models
and made comparisons with healthy control mice [76]. In this study, mouse saliva, blood, salivary
glands, and tumor tissue were collected and RNA extraction was performed. The extracted DNA
was then subject to microarray analysis to compare the transcriptomes of the samples with each other.
These researchers found that the salivary transcriptome in diseased mouse samples had a high number
of overlaps with the salivary gland transcriptomes. Their conclusion was that there are multiple
sources of salivary mRNA. An understanding of these sources better allows researchers to target high
concentrations of biomarkers and identify/validate the diseases associated with them.
An additional branch of investigation that has yielded fruitful results is the presence of microRNA
in saliva. MicroRNA (miRNA) can be defined as a short RNA sequence, approximately 19–25 base pairs
in length, that plays a role in the regulatory process of the cell by inhibiting transcription of sequences
(consequently preventing protein synthesis) and causing messenger RNA degradation [77]. Clinical
examination of miRNA has noted that miRNA sequences miR-125a and miR-200A are expressed lower
in patients with oral squamous cell carcinoma [78]. Analysis of RNA in saliva using RNA sequencing
has also led to the discovery of circular miRNA sequences [79].
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In terms of oral epigenomics, the basis of the study is evaluating the changes and differences of
downstream phenotypes or gene expression that are not a result of genetic heredity. Based on epigenetic
differences in DNA regulation and histone modification, changes between a control subject and a
diseased subject are easily discernible. In addition to epigenetic changes caused by the DNA regulation
or histone modification, epigenetic changes may be a result of invading pathogens as well. Similar to
transcriptomic analysis, qPCR of these epigenetic samples will yield differences between tumor and
control samples [6]. As a result, by combining the analytical tools of transcriptomic analysis and the
changes in oral epigenomics, a patient’s condition can be appropriately assessed. In an overarching
view, both epigenomics and transcriptomic analysis all pertain to the basic genomic analysis of salivary
biomarkers. By analyzing these biomarkers in the methods listed above for transcriptomic analysis,
the genomic differences in patients can be identified and validated.
4.5. Metabolomics
Metabolites are those small compounds that are the small-molecule products that exist as
the body undergoes its metabolic processes [80]. Metabolomic investigation in saliva seeks to
catalog these different small molecules in oral fluid and determine if they can be diagnostically
useful for detection. To analyze the patient’s metabolic profile, multiple analytical platforms can
be used to discern discrepancies in the patients’ saliva chemical fingerprint. These platforms
include nuclear magnetic resonance spectroscopy, gas chromatography mass spectrometry, direct flow
injection/liquid chromatography mass spectrometry, inductively coupled plasma mass spectrometry,
and high-performance liquid chromatography [81]. Using a combination of diagnostic tools, Dame et al.
was able to identify and annotate 308 salivary metabolites in human saliva [82]. A notable highlight of
metabolomic research was conducted at the University of California Los Angeles by Sugimoto et al.
in examining the metabolic profile of patients with lung cancer, breast cancer, pancreatic cancer, and
diabetes [83]. These researchers utilized capillary electrophoresis time of flight mass spectroscopy,
a technique which allowed the separation of different metabolites from saliva and enabled their
profiling through the consequent application of mass spectroscopy. After analyzing the compound
migration and mass spectroscopy data of the clinical specimens and fitting them to known mass-spec
and mobility data using computational algorithms, 57 metabolites were selected as candidates that
could be used for disease identifications. Some of the results of this study were quite encouraging,
including pancreatic cancer having an AUC value of 0.993.
There are a number of additional applications for metabolomics analysis of saliva in diagnostics.
Aimetti et al. [84] reported on periodontal disease metabolites in saliva, and Kageyama et al. [85]
and Mikkonen et al. [86] have both conducted an examination of Sjögren’s syndrome metabolomics.
Kageyama et al. [85] noted that Sjögren’s syndrome patients express a smaller set of metabolites
compared to healthy controls [85], and Mikkonen et al. [86] performed analysis of nuclear
magnetic resonance (NMR) spectroscopy, noting significantly increased levels of alanine and
glycine. Furthermore, metabolomics monitoring has also been examined as a metric method for
evaluating radiation exposure [87]. The results presented by these authors on salivary samples are
suggestive works of the potential of salivary metabolomics profiling for a variety of disease and
healthcare applications.
5. Electric Field-Induced Release and Measurement (EFIRM)
One of the most critical emerging technologies that has been explored for both mechanistic
and clinical studies of salivary diagnostics is the electric field-induced release and measurement
(EFIRM) method. This method is an electrochemical-based technique that emerged at the
University of California, Los Angeles, out of research in developing biomarker detection tools for
salivary diagnostics.
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There are a few distinct features that characterize the EFIRM methodology. Firstly, the platform is
able to immobilize a high density of probes specific to circulating tumor DNA targets on a surface.
These DNA probes are even able to specifically differentiate single base-pair mutations. The second
predominant feature of the EFIRM is the usage of low-voltage electric fields to guide the hybridization
process and lysing exosomes that contain key content. The third major feature of the method is the
usage of an amplification step in order to specifically amplify the signal of the captured biomarker
target and allow quantification through electrochemical reaction of the reaction between a peroxidase
enzyme and tetramethylbenzidine (TMB) and hydrogen peroxide.
These features of EFIRM have allowed for it to be rapidly configured to a variety of
specific contexts:
1. Basic Science: Complementing the diagnostic evaluation of saliva in a clinical setting is the
need for rigorous scientific understanding of saliva’s relation to distal diseases. Specifically, this
involves examining model systems (whether cell-based or animal-model based) in a rigorous and
systematic fashion, which allows us to thoroughly understand the nature of salivary biomarkers
and why biomarkers can often be found in the oral cavity. At present, there is intense interest in
evaluating exosomes—microvesicular structures 30–100 nm in diameter found in saliva and other
biofluids. They have been found to contain proteins, DNA, mRNA, and noncoding RNAs. Thus,
some hypothesize that these exosomes may be the pathway where information is being carried
from one portion of the body to another. Already, exosomes have been examined as prognostic
markers for diseases such as lung cancer, squamous cell carcinoma, and breast cancer [42,88–91].
In examining exosomal entities as a possible transmitter of biomarkers to the oral cavity, EFIRM
was used in conjunction with magnetic beads to extract exosomes from saliva, rapidly use electric
fields to cause cargo unloading, and capture exosomal reference markers [88]. This method
was used by Lau et al. for examining tumor-derived exosomes in a pancreatic cancer mouse
model [42].
2. Translational Research: In regards to the clinical utility of the EFIRM method, EFIRM has
been deployed on a number of clinical contexts. EFIRM was first deployed for successfully
performing multiplexed targeting of the IL-8 protein and IL-8 mRNA markers for oral
cancer [92]. More recently, EFIRM has taken an exciting direction forward by being able to detect
nonsquamous cell lung cancer (NSCLC) oncogenic mutations, which determine the susceptibility
of NSCLC to treatment by tyrosine kinase inhibitors. This examination of the ability to detect
oncogenic mutations also showed high correlation. Most notably, EFIRM was able to successfully
identify mutations in the endothelial growth factor receptor (EGFR) within saliva samples with a
clinical sensitivity and specificity above 95% in two blinded cohort groups [93,94].
These results are indicative of the great potential of the EFIRM platform for performing detection
of a variety of biomarker targets in different contexts. That this technique possesses the ability to
perform noninvasive diagnostics with such extremely high sensitivity and specificity is an exciting
development in the field of saliva diagnostics, and it demonstrates that saliva is quickly becoming a
noninvasive, well-credentialed diagnostic medium that cannot be ignored. As the field of liquid biopsy
is rapidly becoming more ascendant in the recent years, EFIRM has high potential as a liquid biopsy
platform that can perform PCR-free rapid biodetection of oncogenic targets with a small volume of
saliva, an exciting rapid point-of-care method amidst a field dominated by traditional technologies
such as next-generation sequencing or PCR-based technologies [95].
6. Conclusions and Future Direction
This article has given a broad overview of the nature of research in molecular diagnostics in regard
to saliva. The key fields of investigation for salivary diagnostics have been discussed and important
studies have been highlighted. Studies already conducted show the great promise of different salivary
biomarkers, and doubtless our ever-expanding knowledge of salivary biomarkers coupled with the
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potential present in combining multiple markers from different “omics” fields can possibly make
molecular profiling for disease in saliva even more effective.
Also highlighted were some key trends to watch for in the field of salivary diagnostics. Studies that
are working towards definitive validation of salivary biomarkers in large patient cohorts offer promise
of rigorous validation that can approach the levels necessary for approval by the FDA. Furthermore,
the usage of novel technologies such as the EFIRM platform shows the potential for rapid noninvasive
detection of oncogenic mutations, demonstrating that saliva as a diagnostic medium is more than an
academic interest: saliva is quickly becoming a biofluid that is well-credentialed, and convenient and
noninvasive in its collection.
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